Metraipolis › archive › dc_76754575ea5b

An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs.… — Europe PMC PMID:33591979

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/33591979
DOI
10.1371/journal.pntd.0009069
License (as archived)
CC0-1.0
Archived
2026-11-05T22:46:14.092Z
SHA-256 of the archived text
93acda651a07bd178c8a35df3ebe1e06fe3696d9f508bdfb7c9e5f178920da07
Stable URL of this page
https://metraipolis.com/documento/dc_76754575ea5b

How to cite

An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs.… — Europe PMC PMID:33591979 — Europe PMC (en), https://europepmc.org/article/MED/33591979 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_76754575ea5b (Metraipolis archive dc_76754575ea5b, sha256 93acda651a07bd178c8a35df3ebe1e06fe3696d9f508bdfb7c9e5f178920da07)
BibTeX
@misc{dc76754575ea5b,
  title = {An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs.… — Europe PMC PMID:33591979},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/33591979},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_76754575ea5b; sha256 93acda651a07bd178c8a35df3ebe1e06fe3696d9f508bdfb7c9e5f178920da07},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/33591979. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis (LF). This community study was designed to compare the safety and efficacy of MDA with IDA (ivermectin, diethylcarbamazine and albendazole) or DA (diethylcarbamazine and albendazole) in India. Methodology/principal findings: This two-armed, open-labelled, block randomised, community study was conducted in LF endemic villages in Yadgir district, Karnataka, India. Consenting participants ≥5 years of age were tested for circulating filarial antigenemia (CFA) and microfilaremia (Mf) before treatment with a single oral dose of IDA or DA. Adverse events (AEs) were monitored actively for two days and passively for five more days. Persons with positive CFA or Mf tests at baseline were retested 12-months post-treatment to assess treatment efficacy. Baseline CFA and Mf-rates were 26.4% and 6.9% in IDA and 24.5% and 6.4% in DA villages respectively. 4758 and 4160 participants received IDA and DA. Most AEs were mild after both treatments; fewer than 0.1% of participants experienced AEs with severity > grade 1. No serious AEs were observed. Fever, headache and dizziness were the most common AEs. AE rates were slightly higher after IDA than DA (8.3% vs. 6.4%, P<0.01). AEs were more frequent in females and Mf-positives after either treatment, but significantly more frequent after IDA (40.5% vs 20.2%, P < 0.001). IDA was more effective for clearing Mf than DA (84% vs. 61.8%, P < 0.001). Geometric mean Mf counts per 60μl in retested Mf-positives decreased by 96.4% from 11.8 after IDA and by 90.0% from 9.5 after DA. Neither treatment was effective for clearing CFA. Conclusions/significance: IDA had an acceptable safety profile and was more effective for clearing Mf than DA. With adequate compliance and medical support to manage AEs, IDA has the potential to accelerate LF elimination in India. Trial registration: Clinical Trial Registry of India (CTRI No/2016/10/007399).

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS neglected tropical diseases, 2021 (prima pubblicazione 2021-02-16).
Identificativi: PMID 33591979 · PMCID PMC7909694 · DOI 10.1371/journal.pntd.0009069.
Pagina: https://europepmc.org/article/MED/33591979 — https://doi.org/10.1371/journal.pntd.0009069. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-05T22:42:47.957Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.